Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
anticoagulant
Biotech
BMS, J&J's secondary stroke med doesn't stick the landing
Bristol Myers Squibbs' anticoagulant milvexian failed its phase 2 trial but accrued enough encouraging data for the company to prep phase 3 plans.
Max Bayer
Aug 28, 2022 3:36am
Racing Bayer, Merck gets FDA fast-track tag for anticoagulant
Aug 23, 2022 8:40am
Bayer-Ionis' anti-thrombotic med doesn't increase bleeding
Jul 28, 2022 10:51am
Amag merges with Perosphere, adding NOAC antidote
Dec 13, 2018 9:55am
Boston Sci to distribute Veniti’s venous stent
Sep 11, 2017 11:31am
Roche debuts iOS app for blood coagulation test device
Sep 26, 2016 11:18am